American Association for Cancer Research

Poster Session B

Poster Session B
Monday, March 1
8:00 p.m.-10:30 p.m.

In alphabetical order, not board assignment order

  • 3’end processing of telomerase RNA in fission yeast. Wen Tang, Peter Baumann. Stowers Institute for Medical Research, Kansas City, MO.
  • A genome-wide short hairpin RNA screen identifies Klotho beta as a gene which can overcome stasis in human colonic epithelial cells. Jinyong Kim, Ugur Eskariok, Guido Stadker, Zhenjun Lou, Makoto Kuro-O, Jerry W. Shay, Woodring E. Wright. UT Southwestern Medical Center, Dallas, TX.
  • A human mammary epithelial cell system to study the reactivation of telomerase activity during carcinogenic progression. James C. Garbe1, Andrew J. Wyrobek1, Bernard W. Futscher2, Martha R. Stampfer1. 1Lawrence Berkeley National Laboratory, Berkeley, CA, 2Arizona Cancer Center, Tucson, AZ.
  • A mutation in MRE11 that influences telomere recombination pathways and promotes an efficient bypass of telomere senescence. Arthur J. Lustig, Alpana Kumari, Immanual S. Joseph, Mrinal Bhattaracharyya. Tulane University, New Orleans, LA.
  • A novel G-quadruplex ligand markedly inhibits the growth of telomerase-positive and ALT-positive human cancer cell lines and breast tumor initiating cells. Marco Folini1, Claudia Sissi2, Giuseppe Zagotto2, Mara Binda1, Maria Grazia Daidone1, Manlio Palumbo2, Nadia Zaffaroni1. 1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 2University of Padua, Padua, Italy.
  • A small-molecule telomerase activator prevents the development of lung fibrosis in bleomycin mouse model. P. Davy1, C. Jourdan Le Saux1,2, C. Brampton1, R.Tressler3, Calvin Harley3, R. Allsopp1. 1University of Hawaii John A. Burns School of Medicine, Honolulu, HI, 2UT Health Science Center at San Antonio, San Antonio, TX, 3Geron Corp., Menlo Park, CA.
  • Alternative spliced variants of TERT have extratelomeric function. Radmila Hrdlickova, Jiri Nehyba, Henry R. Bose. University of Texas, Austin, TX.
  • Alternative splicing and promoter hypermethylation cooperate in the upregulation of hTERT expression and telomerase activity during gastric carcinogenesis. Xin Geng1, Fei Wang2, Wei Ming Zhang1. 1Tianjin Medical University, Tianjin, China, 2General Hospital, Tianjin Medical University, Tianjin, China.
  • Artificial tethering of Cdc13 to ‘poisoned’ Kluyveromyces lactis telomeres rescues cell viability by a Rad52-dependent mode of telomere capping. Noa Lamm, Shhadeh Bsoul, Majdi M. Kabaha, Yehuda Tzfati. The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Biochemical study of Ccq1 for activity control of fission yeast telomerase. Motoki Saito, Tomoichiro Miyoshi, Junko Kanoh, Fuyuki Ishikawa. Graduate School of Kyoto University, Kyoto, Japan.
  • Changing dynamics of telomerase action on mammalian telomeres. Yong Zhao1, Eladio Abreu2, Jinyong Kim1, Michael Terns2, Rebecca Terns2, Jerry Shay1. 1 UT Southwestern Medical Center, Dallas, TX, 2University of Georgia, Athens, GA.
  • Characterizing a putative nuclear localization sequence in the Est1p component of telomerase that contributes to telomere maintenance. Charlene Hawkins, Katherine L. Friedman. Vanderbilt University, Nashville, TN.
  • Chromosome arm-specific telomere length and breast cancer risk. Yun-Ling Zheng1, Xin Zhou1, Christopher A. Loffredo1, Peter G. Shields1, Bing Sun2. 1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, 2BioMarkers, Rockville, MD.
  • Conservation of telomerase inhibition by Xenopus PinXI. David A. Constant, Jayne T. Gaubatz, Patrick Fink, Molly M. King, Sophie E. Mayer, Mark Amoruso, Janis Shampay. Reed College, Portland, OR.
  • Erucin-mediated growth suppression of human HCC cells is preceded by hTERT degradation independent from the tumor suppressor p53. Evelyn Lamy, Meike Wagner, Volker Mersch-Sundermann. University Medical Center Freiburg, Freiburg, Germany.
  • Evidence for chromosome end protection by two distinct telomere architectures. Anita Kazda, Barbara Zellinger, Karel Riha. Gregor Mendel Institute of Molecular Plant Biology, Vienna, Austria.
  • Expression of telomeres in astrocytic brain tumors and correlation with telomerase activity, telomere length, and malignancy grade. Sandra Sampl, Christian Stern, Johannes Hainfellner, Matthias Preusser, Christine Marosi, Klaus Holzmann. Medical University Vienna, Vienna, Austria.
  • FEN1 facilitates replication fork reinitiation and ensures telomere stability. Saharia Abhishek, Daniel C. Teasley, Benjamin Dao, Katherine B. Chiappinelli, Sheila A. Stewart. Washington University, St. Louis, MO.
  • Generation and characterization of an EGFP-TRF1 knock-in reporter mouse as a new tool for telomere analysis in living cells and mice. Ralph Philipp Schneider, Ignacio Flores, Maria A. Blasco. CNIO, Madrid, Spain.
  • High prevalence of TERT mutations in hematopoietic cancers. Mark Hills1, Alexander Roeth2, Holger Nuckel2, Doug Horsman3, Jan Durig2, Randy D. Gascoyne1, Irma Vulto1, Peter M. Lansdorp1. 1Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada, 2University Hospital Essen, Essen, Germany, 3BC Cancer Control Agency, Vancouver, BC, Canada.
  • ICF syndrome as a human model for studying the role of human subtelomeric methylation in regulation of telomere length and function. Shiran Yehezkel, Yardena Segev, Karl Skorecki, Sara Selig. Technion Faculty of Medicine and Rambam Medical Center, Haifa, Israel.
  • Induction of ALT pathway in radiation induced osteosarcomas. Iria Gonzalez-Vasconcellos, Bahar Sanli-Bonazzi, Michael J. Atkinson, Michael Rosemann. Institute of Radiation Biology, Helmholtz Zentrum, Munich, Germany.
  • In vivo and in vitro inhibition of multiple types of cancer stem cells by the novel telomerase inhibitor imetelstat. Immanual Joseph1, William Matsui2, Caterina A. M. LaPorta3, Uri Tabori4, Harley Kornblum5, Brittney-Shea Herbert6, Calvin Harley1, Robert Tressler1. 1Geron Inc., Menlo Park, CA, 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 3University of Milan, Milan, Italy, 4The Arthur and Sonia Labatt Brain Tumor Research Centre, The Hospital for Sick Children, Toronto, ON, Canada, 5Devid Geffen School of Medicine at UCLA, Los Angeles, CA, 6Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.
  • In vivo treatment with imetelstat inhibits telomerase in xenograft tumors, mouse bone marrow, human PBMC, hair follicles, and human bone marrow. Ning F. Go1, Laurence Elias1, Tressler Robert1, Bass Kathy1, Zhu Pirot1, Tong Lin1, Lane Eubank1, Jennifer Smith1, Calvin Harley1, Fabio Benedetti1, Pat LoRusso2, Mark J. Ratain3. 1Geron Corp., Menlo Park, CA, 2Karmanos Cancer Institute, Detroit, MI, 3University of Chicago, Chicago, IL.
  • Late S/G2 phase-specific C-strand fill-in at human telomeres requires lagging-strand synthesis machinery and is important for maintaining functional telomeres. Amruta Bhusari1, Chenhui Huang2, Weihang Chai2. 1Texas Woman’s University, Denton, TX, 2Washington State University, Spokane, WA.
  • Nuclear organization of chromosome territories and consequences of a single telomere loss. Claire Heride1, Géraldine Pottier1, Karine Dubrana1, Johan Von Hase2, Christoph Cremer2, John P. Murnane3, Laure Sabatier1. 1CEA-DSV-LRO, Fontenay-Aux-Roses, France, 2KIP, Heidelberg, Germany, 3University of California, San Francisco, CA.
  • Phosphorylation of Cdc13p by Tel1p/Mec1p kinases facilitates Est1p recruitment to telomere end. Yun Wu, Virginia A. Zakian. Princeton University, Princeton, NJ.
  • RecQ helicases interact with shelterin proteins and take part in maintenance and repair of telomeric DNA. Avik Ghosh1, Marie Rossi1, Patricia Opresko2, Vilhelm Bohr1. 1National Institute on Aging, Baltimore, MD, 2University of Pittsburgh, Pittsburgh, PA.
  • Reduction of telomerase activity in human breast carcinoma cells by adenoviral-mediated overexpression of E2F-1. Yanna Liu, Flavio Palalon, Keyomarsi Khandan, Stephen G. Swisher, Kelly K. Hunt. UT M. D. Anderson Cancer Center, Houston, TX.
  • Regulation of telomerase expression and activity by androgen in prostate cancer cell line. Sheeba Jacob, Uddhav Choudhari, Chander P. Puri, Geetanjali Sachdeva. National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India.
  • Reptin is required for the transcription of telomerase reverse transcriptase and overexpressed in gastric cancer. Dawei Xu1, Wenjuan Li2, Jiping Zeng2, Qiao Li1, Jihui Jia2, Magnus Björkholm1.1Karolinska Institute, Stockholm, Sweden, 2Shandong University, Jinan, China.
  • Reversible immortalization of dystrophic myoblasts to study the involvement of telomere length in facioscapulohumeral muscular dystrophy. Guido Stadler1, Jennifer Chen2, Jerome Robin1, Charles P. Emerson, Jr.2, Kathryn Wagner3, Jerry W. Shay1, Woodring E. Wright1. 1UT Southwestern Medical Center, Dallas, TX, 2Boston Biomedical Research Institute, Watertown, MA, 3Center for Inherited Muscle Disorders, The Kennedy Krieger Institute, Baltimore, MD.
  • S. cerevisiae Est1p is recognized by the anaphase promoting complex for degradation during G1 phase of the cell cycle. Jenifer L. Ferguson, Katherine L. Friedman. Vanderbilt University, Nashville, TN.
  • S. pombe telomerase RNA mutational analysis and identification of protein interactors. Christopher J. Webb, Virginia A. Zakian. Princeton University, Princeton, NJ.
  • Telomerase and telomeres are the targets of PCBs: A new mechanism in the field of PCB carcinogenesis. Senthilkumar Perumal Kuppusamy, James A. Jacobus, Hans Joachim Lehmler, Larry W. Robertson, Gabriele Ludewig. University of Iowa, Iowa City, IA.
  • Telomerase dependence of tumor-initiating cells differs from the bulk of tumor cells and normal tissue stem cells resulting in a specific and safe target for telomerase inhibition by imetelstat. Pedro Castelo-Branco1, Cindy Zhang1, Loen Hansford1, Tatiana Lipman1, Mayumi Fujitani1, Ian Clarke1, Calvin Harley2, Robert Tressler2, Ning Go2, Katia Bassett2, David Malkin1, David Kaplan1, Peter Dirks1, Uri Tabori1. 1The Hospital for Sick Children, Toronto, ON, Canada, 2Geron Corporation, Menlo Park, CA.
  • Telomere dysfunction-induced senescence limits human cancer progression. Anitha Suram1, Haihe Ruan1, Jessica Fishlock1, Virginia Boccardi1, Neena Mirani1, Marzia Fumagalli2, Raffaella di Micco2, Resham Lal Gurung3, Manoor Prakash Hande3, Fabrizio d’Adda di Fagagna2, Utz Herbig1. 1New Jersey Medical School-UMDNJ, Newark, NJ, 2FIRC Institute of Molecular Oncology Foundation, Milan, Italy, 3National University of Singapore, Singapore.
  • Telomere loss and telomere aggregation: Two mechanisms contributing to skin cancer development and progression. Petra Boukamp, Damir Krunic, Yetunde Otunsi, Christine Baderschneider, Jutta Leykauf, Karin Greulich German Cancer Research Center, Division of Genetics of Skin Carcinogenesis, Heidelberg, Germany.
  • Telomere reprogramming in iPS cells lacking histone methyltranferases or individual components of the shelterin complex. Rosa M. Marión, Maria A. Blasco. Spanish National Cancer Research Centre, Madrid, Spain.
  • Telomere, telomerase, and cancer in a prosimian primate, the grey mouse lemur (Microcebus murinus). Delphine Trochet1, Fabienne Aujard2, Jean-Louis Mergny3, Martine Perret2, Jean-Francois Riou1. 1Régulation et Dynamique des Génomes, INSERM U565, CNRS UMR7196/MNHN, Paris, France, 2Mécanismes Adaptatifs et Evolution, UMR CNRS/MNHN 7179, Brunoy, France, 3Laboratoire ARNA (INSERM U869) Institut Européen de Chimie et Biologie, Bordeaux, France.
  • Terminal genome rearrangements triggered by telomere erosion. Mia Lowden, Shawn Ahmed. University of North Carolina, Chapel Hill, NC.
  • TERRA-bound RNA binding proteins. Isabel López de Silanes, Martina Stagno d’Alcontres, Maria Antonia Blasco. Spanish National Cancer Research Centre, Madrid, Spain.
  • The effect of proinflammatory conditioning and/or high glucose on telomere shortening of aging fibroblasts. Cecilia G. Maubaret, Klelia D. Salpea, Steve E. Humphries. University College London, London, United Kingdom.
  • TRF2 and Apollo cooperate with topoisomerase 2α to protect human telomeres from replicative damage. Jing Ye1, Christelle Lenain1, Serge Bauwens1, Annamaria Biroccio2, Arturo Londoño-Vallejo3, Marie-Josèphe Giraud-Panis1, Eric Gilson1. 1Laboratoire de Biologie Moléculaire de la Cellule, Ecole Normale Supérieure de Lyon, Lyon, France, 2Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Roma, Italy, 3Institut Curie, Paris, France.
  • xTRF2 is required for telomere replication in Xenopus egg extracts. Keiko Muraki1, Hidenori Nakaoka1, Akira Nabetani1, Atsuya Nishiyama2, Fuyuki Ishikawa1. 1Kyoto University, Kyoto, Japan, 2IGH, CNRS, Montpellier, France.